Lung transplantation for sarcoidosis: outcome and prognostic factors

Study question In patients with sarcoidosis, past and ongoing immunosuppressive regimens, recurrent disease in the transplant extrapulmonary involvement may affect outcomes of lung transplantation. We asked whether sarcoidosis phenotypes can be differentiated and, if so, how they relate to pulmonary treated by Patients methods retrospectively reviewed data from 112 who met international diagnostic criteria for underwent or heart–lung transplantation between 2006 2019 at 16 European centres. Results Patient survival was main outcome measure. At transplantation, median (interaquartile range (IQR)) age 52 (46–59) years; 71 (64%) were male. Lung individualised as follows: 1) extended fibrosis only; 2) airflow obstruction; 3) severe hypertension (sPH) 4) sPH, obstruction fibrosis; 5) sPH 6) 7) sPH; 8) none these criteria, 17%, 16%, 14%, 11%, 9%, 5% 11% patients, respectively. Post-transplant rates after 1, 3, 5 years 86%, 76% 69%, During follow-up (median (IQR) 46 (16–89) months), 31% developed chronic allograft dysfunction. Age associated increased mortality. Pulmonary predominating peripherally short-term complications. Answer study similar that other indications The factors worse older extensive pre-operative fibrosis.